I ask whether Theranos could be contracted by health plans today, and I argue that our current gates often check paperwork rather than test performance. I walk through four gates: CLIA certification, state and FDA rules, Medicare enrollment checks, and commercial payer contracting. I note that CLIA and state reviews eventually caught Theranos, but payers and investors did not detect the fraud. I explain that a reporter and regulators exposed the problem years into the misconduct, which shows a dangerous lag. I say the system needs earlier and stronger checks on test validity and real performance. I invite listeners to share their thoughts and questions in the comments.

I recount the arc of Theranos as I observed it and as the documentary presents it. I describe Elizabeth Holmes’s claim that a finger‑prick device could deliver a wide range of blood tests faster and cheaper. I relate how internal staff raised concerns, how a Wall Street Journal investigation revealed inconsistencies, and how federal inspectors found grave laboratory deficiencies that led to mass invalidation of results and regulatory penalties. I explain the criminal outcome: convictions for investor fraud, acquittals on patient counts, and the subsequent sentence adjustments. I also recount the documentary material that shows Holmes and her partner discussing a purported Theranos 2.0, and how the film offers intimate access to their lives while leaving unresolved questions about motive and responsibility. My narration emphasizes the disconnect between the public story of innovation and the private realities uncovered by regulators and reporters. I close by stressing the human costs: nearly a million invalidated tests and unanswered questions about how the system allowed that divergence to persist for years.

Takeaways:

• I argued that existing regulatory gates like CLIA and state lab licensing often check paperwork rather than actual test performance.
• I noted that Medicare enrollment requires disclosure of owners and legal history but may not reliably bar determined bad actors.
• I emphasized that many payer and investor gates failed to detect Theranos fraud early, allowing dangerous delays before exposure.
• I recounted how journalists and CMS inspections ultimately exposed the company, demonstrating a significant lag between payments and regulatory detection.
• I warned that weak scientific verification enables companies with seemingly clean founders to obtain payer contracts despite invalid test results.

Companies mentioned in this episode:

• Theranos
• NBC News
• The Wall Street Journal
• Walgreens
• Humana Health Plan
• Capital Blue Cross
• AmeriHealth Caritas
• LabCorp
• Quest Diagnostics